FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Mallinckrodt Complete Response on Terlipressin NDA

FDA issues a second complete response letter in less than 18 months to Mallinckrodt for its NDA for terlipressin to treat adults with hepatorenal synd...

Human Drugs

28-Page FDA-483 for Edge Pharma Inspection

FDA releases a lengthy FDA-483 with 13 observations from a two-month inspection at Colchester, VT-based Edge Pharma drug outsourcing facility.

Biologics

Sanofi/GSK to Submit Covid Vaccine Data

Sanofi and GlaxoSmithKline say a Phase 3 trial of their Covid-19 vaccine showed it was 100% effective against severe Covid disease and hospitalization...

Human Drugs

AbbVie Seeks Vraylar OK for Major Depression

AbbVie files a supplemental NDA for Vraylar (cariprazine) for the adjunctive treatment of major depressive disorder in patients who are receiving ongo...

Human Drugs

CDER Webinar on Improving Biosimilar Adoption

CDER announces a 4/13 Webinar entitled Biosimilars: A Decade of Experience and Future DirectionsStrategies for Improving Biosimilar Adoption and the P...

Medical Devices

Baxter Safety Alert on Spectrum Infusion Pumps

Baxter International issues an urgent safety communication on upstream occlusion alarms for all Spectrum V8 and Spectrum IQ infusion pumps.

Human Drugs

Ferring Wants Restrictions on Firmagon Generics

Ferring petitions FDA to require in vivo testing for ANDA and follow-on applications citing the companys Firmagon as the reference-listed drug.

Medical Devices

Class 1 Recall of E25Bio Covid-19 Test

FDA classifies as Class 1 a recall of the E25Bio Covid-19 Direct Antigen Rapid Test because it has not been authorized, cleared, or approved by the ag...

Human Drugs

FDA Approves 1st Generic Drug Based on PBPK Model

FDA says it was able to approve a generic diclofenac sodium topical gel using an alternative method to determine bioequivalence.

Human Drugs

People Want More FDA Transparency: Survey

Johns Hopkins researchers say a survey of U.S. adults shows people want much more transparency from FDA.